Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Top advances in lymphoma for 2021
Dilan A. Patel
,
Brad S. Kahl
Section of Medical Oncology
Siteman Cancer Center
Research output
:
Contribution to journal
›
Comment/debate
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Top advances in lymphoma for 2021'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Lymphoma
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Indolent Lymphoma
100%
Cellular Products
100%
Prednisone
50%
Chemotherapy Resistance
50%
T Cells
50%
Elderly Patients
50%
Tonic
50%
Bispecific
50%
Diffuse Large B-cell Lymphoma (DLBCL)
50%
Autologous Transplantation
50%
Antibody-drug Conjugate
50%
B-cell Receptor Signaling
50%
Doxorubicin
50%
Rituximab Plus Cyclophosphamide
50%
Multiple Lines
50%
Chimeric Antigen Receptor T-cell Therapy
50%
Aggressive Lymphoma
50%
High Response Rate
50%
Marginal Zone Lymphoma
50%
Resistant Disease
50%
Cytotoxic Drugs
50%
Later-line Treatment
50%
PI3K Inhibitor
50%
Zanubrutinib
50%
Mosunetuzumab
50%
Redirector
50%
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell
100%
Elderly Patient
50%
T Cell
50%
Diffuse Large B-Cell Lymphoma
50%
Rituximab
50%
Autotransplantation
50%
B Lymphocyte Receptor
50%
Doxorubicin
50%
Cyclophosphamide
50%
Prednisone
50%
Vincristine
50%
Spine
50%
MALT Lymphoma
50%
Chimeric Antigen Receptor T-Cell Immunotherapy
50%
Zanubrutinib
50%
Mosunetuzumab
50%
Aggressive Lymphoma
50%
Diseases
50%
Cytotoxic Agent
50%